Androgen sensitivity gateway to COVID ‐19 disease severity
May 2020
in “Drug Development Research”
TLDR Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
The document hypothesizes that androgen sensitivity, influenced by genetic variants of the androgen receptor, may be a crucial factor in determining the severity of COVID-19. This could account for the observed higher severity in males, lower impact on children, and varying mortality rates among ethnicities. The androgen receptor is involved in regulating TMPRSS2, which is essential for SARS-CoV-2 infectivity. Epidemiological data, including a study of 5,700 patients in New York and another from Wuhan, China, support the hypothesis by showing higher male fatalities and complications. Additionally, a notable incidence of androgenetic alopecia among hospitalized male COVID-19 patients was observed. The paper suggests that anti-androgen agents could be a potential treatment for COVID-19, with ongoing clinical trials exploring this avenue. It also considers that while androgens may significantly influence COVID-19 severity, other pathways for infection could exist.
View this study on onlinelibrary.wiley.com →
Cited in this study
research What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy
Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
research A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
Male pattern hair loss could hint at androgens affecting COVID-19 severity.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.